A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

计划入组 100 人 · 首次发布于 2026 年 3 月 11 日

MK-0524B Lipid Study (MK-0524B-063)

计划入组 2,414 人 · 首次发布于 2007 年 5 月 28 日

Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

计划入组 94 人 · 首次发布于 2015 年 11 月 24 日

MK-434

MK-0873

C₂₅H₁₈N₄O₃

MK-0608

Merck Assumes Full Control of MK-8690 Anti-CD30 Ligand Antibody for Inflammatory Bowel Disease

Lantheus' Alzheimer's Radiodiagnostic MK-6240 Achieves Pivotal Study Success, NDA Filing Planned

Merck Discontinues In-House TROP2 ADC MK-6837 After Revealing Dual Development Strategy